

# Supplementary Appendix for: Diagnostic performance of non-invasive fibrosis markers for chronic hepatitis B in sub-Saharan Africa: a Bayesian individual patient data meta-analysis

## Contents

<b>Appendix 1: Search methodology</b> .....	2
<b>Appendix 2: List of variables reported by HEPSANET participating sites</b> .....	3
<b>Appendix 3: Characteristics of study sites</b> .....	5
<b>Appendix 4: Description of bivariate random effects model</b> .....	6
<b>Appendix 5: Validation of APRI model for cirrhosis using 500 bootstrap samples</b> .....	8
<b>Appendix 6: Ethical approval HEPSANET</b> .....	9
<b>Appendix 7: Flowchart of searches for eligible studies</b> .....	10
<b>Appendix 8: Risk of bias assessment using the QUADAS-2 criteria</b> .....	11
<b>Appendix 9: Association of cirrhosis prevalence with age, sex, and reason for hepatitis B testing<sup>a</sup></b> 13	
<b>Appendix 10: Associations with cirrhosis (model 1) and significant fibrosis (model 2) among HEPSANET participants: mixed effects logistic regression model<sup>a</sup></b> .....	14
<b>Appendix 11: Diagnostic performance characteristics at each site, stratified by reason for testing using APRI with rule-out threshold of 0.65 for the diagnosis of cirrhosis</b> .....	15
<b>Appendix 12: Association between participant characteristics and biomarker sensitivity and specificity for the diagnosis of cirrhosis (&gt;12.2kPa) with APRI and GPR set at rule-in thresholds: Bayesian bivariate random effects model<sup>a</sup></b> .....	16
<b>Appendix 13: Sensitivity analyses of rule-in and rule-out thresholds for APRI assessing the effect of exclusion of patients with ascites, use of sex-specific and centre-specific upper limits of normal, and use of an alternative liver stiffness threshold of 9.5 kPa to define cirrhosis</b> .....	17
<b>Appendix 14: Association between liver stiffness measurement and test sensitivity for APRI: Liver stiffness distribution stratified by APRI classification (A &amp; B) and sensitivity of APRI relative to liver stiffness (C &amp; D) among patients with cirrhosis</b> .....	18

## Appendix 1: Search methodology

Search date: 6<sup>th</sup> October 2020, no language or publication date restrictions applied

### PUBMED (<https://pubmed.ncbi.nlm.nih.gov/>)- 697 results

("liver cirrhosis"[MeSH] OR "elasticity imaging techniques"[MeSH] OR fibrosis[tiab] OR cirrhosis[tiab] OR elastograph*[tiab] OR fibroscan[tiab] OR biopsy, needle[MeSH] OR "liver biops*" [tiab] OR metavir[tiab])
AND (hepatitis B[MeSH] OR hepatitis b[tiab] OR HBV[tiab] OR HBsAg[tiab])
AND (Africa[MeSH] OR Africa*[tiab] OR Angola[tiab] OR Benin[tiab] OR Botswana[tiab] OR "Burkina Faso"[tiab] OR Burundi[tiab] OR Cameroon[tiab] OR "Cape Verde"[tiab] OR "Central African Republic"[tiab] OR Chad[tiab] OR Comoros[tiab] OR Congo[tiab] OR Djibouti[tiab] OR "Equatorial Guinea"[tiab] OR Eritrea[tiab] OR Ethiopia[tiab] OR Gabon[tiab] OR Gambia[tiab] OR Ghana[tiab] OR Guinea[tiab] OR "Guinea Bissau"[tiab] OR "Ivory Coast"[tiab] OR "Cote d'Ivoire"[tiab] OR Kenya[tiab] OR Lesotho[tiab] OR Liberia[tiab] OR Madagascar[tiab] OR Malawi[tiab] OR Mali[tiab] OR Mauritania[tiab] OR Mauritius[tiab] OR Mozambique[tiab] OR Mocambique[tiab] OR Namibia[tiab] OR Niger[tiab] OR Nigeria[tiab] OR Principe[tiab] OR Reunion[tiab] OR Rwanda[tiab] OR "Sao Tome"[tiab] OR Senegal[tiab] OR Seychelles[tiab] OR "Sierra Leone"[tiab] OR Somalia[tiab] OR "South Africa"[tiab] OR Sudan[tiab] OR Swaziland[tiab] OR Tanzania[tiab] OR Togo[tiab] OR Tunisia[tiab] OR Uganda[tiab] OR Zambia[tiab] OR Zimbabwe[tiab])

### SCOPUS (<https://www.scopus.com/search/form.uri> )- 947 results

( TITLE-ABS-KEY ( africa* OR angola OR benin OR botswana OR "Burkina Faso" OR burundi OR cameroon OR "Cape Verde" OR "Central African Republic" OR chad OR comoros OR congo OR djibouti OR "Equatorial Guinea" OR eritrea OR ethiopia OR gabon OR gambia OR ghana OR guinea OR "Guinea Bissau" OR "Ivory Coast" OR "Cote d'Ivoire" OR kenya OR lesotho OR liberia OR madagascar OR malawi OR mali OR mauritania OR mauritius OR mozambique OR mocambique OR namibia OR niger OR nigeria OR principe OR reunion OR rwanada OR "Sao Tome" OR senegal OR seychelles OR "Sierra Leone" OR somalia OR "South Africa" OR sudan OR swaziland OR tanzania OR togo OR tunisia OR uganda OR zambia OR zimbabwe ) )
AND ( TITLE-ABS-KEY ( "elasticity imaging" OR elastograph* OR fibroscan OR "needle biopsy" OR "liver biops*" OR metavir OR cirrhosis OR fibrosis ) )
AND ( TITLE-ABS-KEY ( "hepatitis b" OR hbv OR hbsag ) )

### Africa Index Medicus (<https://indexmedicus.afro.who.int/>) - 11 results

(tw:( "elasticity imaging" OR elastograph* OR fibroscan OR "needle biopsy" OR "liver biops*" OR metavir OR cirrhosis OR fibrosis)) AND (tw:( "hepatitis b" OR hbv OR hbsag))
--

### Africa Journals Online (<https://www.ajol.info/index.php/ajol>) - 260 results

Searched using Google Scholar (<https://scholar.google.com/>)

site:ajol.info (elastography OR liver biopsy OR fibroscan) AND "hepatitis B"
--

## Appendix 2: List of variables reported by HEPSANET participating sites

### 2.1 Centre-specific variables

Variable	Description/ criteria
Country/ locale	Facility location
Study design	Community or hospital based
Criteria used for valid Fibroscan result	Centre definition
HBV DNA platform	Details of assay, manufacturer, platform
Biochemistry platform	Details of assay, manufacturer, platform for liver enzyme quantification
Schistosomiasis epidemiology	Describe whether endemic hepatic schistosomiasis ( <i>S. mansoni</i> )
Schistosomiasis diagnosis	Method of diagnostic evaluation for schistosomiasis among centres with endemic disease
Harmful alcohol definition	Definition used for harmful alcohol consumption

### 2.2 Patient-specific variables (essential variables highlighted in bold)

Variable	Description/ criteria
<b>Patient age</b>	Unit: years
<b>Sex</b>	Male/female
<b>Pregnancy</b>	Current pregnancy
<b>Transient elastography</b>	Fasting (>2 hours) transient elastography result Unit: kPa
<b>Alanine aminotransferase (ALT)</b>	Unit: U/L
<b>Aspartate aminotransferase (AST)</b>	Unit: U/L
<b>Gamma glutamyltransferase (GGT)</b>	Unit: U/L
<b>Platelets</b>	Unit: x10 <sup>9</sup> /L
Bilirubin	Unit: mg/dL
International normalised ratio	Unit: ratio
Hepatitis B e antigen	Positive/ negative
Hepatitis B DNA	Unit: IU/ml
Hepatitis B genotype	Genotype assigned from sequencing
Anti-hepatitis C antibody	Positive/ negative
Hepatitis C RNA	Positive/ negative
Anti-hepatitis D antibody	Positive/ negative
Hepatitis D RNA	Positive/ negative
Body mass index	Unit: kg/m <sup>2</sup>
<b>Reason for testing for hepatitis B</b>	Suspected liver disease, due to clinical features of liver disease, or abnormal liver function tests, or abnormal liver imaging; or asymptomatic screening for antenatal care, or blood donation, or family contact of HBsAg positive individual, or community screening.

<b>Current or past hepatitis B treatment</b>	Comprising tenofovir disoproxil fumarate, tenofovir alafenamide, entecavir, lamivudine, emtricitabine, telbivudine, adefovir, interferon.
Family history of HCC or cirrhosis	First- or second-degree relative with cirrhosis or HCC.
Alcohol abuse	Centre-specific definitions were used.
Type 2 diabetes	Ever diagnosed, or treated for type 2 diabetes mellitus.
Hypertension	Ever diagnosed, or treated for hypertension.
Hyperlipidaemia	Ever diagnosed with, or treated for, hyperlipidaemia.
Hepatic schistosomiasis	Evidence of schistosomal liver disease by radiology + a positive serum/stool/urine test (according to centre-specific diagnostics)
HCC	Liver tumour(s) diagnosed by radiology or histology.
Ascites	Past or current evidence of ascites, by clinical examination and/or radiology.
Jaundice	Clinically diagnosed with jaundice by a clinician
Variceal bleeding	Upper GI bleeding where endoscopy confirms oesophageal varices.
Hepatic encephalopathy	Cerebral dysfunction observed and diagnosed as HE by a clinician.

Appendix 3: Characteristics of study sites

Country	Site	Principle investigator(s)	Facility	Year national HBV vaccine introduced	Number of eligible patients	Endemic Schistosomiasis mansoni	Definition of hazardous alcohol	Biochemistry assay	HBV DNA quantification assay
Ethiopia	Addis Ababa	Desalegn & Johannessen	Referral hospital	2007	1038	No	WHO AUDIT	Humalyzer 3000, Human	HBV Realtime, m2000sp/rt, Abbott & GeneXpert HBV, Cepheid
Gambia	Fajara	Njie & Lemoine	Referral hospital	1990	797	No	>20g/day (none reported)	VITROS 350, Ortho	In-house assay LLQ=50 IU/ml
Senegal	Dakar	Mbaye & Vray	Secondary hospitals (4)	2005	169	No	Not reported	Not reported	Cobas Ampliprep/Taqman v1.0, Roche
Nigeria	Jos	Okeke	Referral hospital	2004	190	Yes	CAGE questionnaire	Cobas, Roche	In-house assay LLQ=20 IU/ml
South Africa	Cape Town	Spearman & Sonderup	Referral hospital	1995	155	No	WHO AUDIT	Coba 6000, Roche	Cobas Amplicor, Roche
Malawi	Blantyre	Stockdale	Referral hospital	2002	97	Yes	WHO AUDIT	AU480, Beckman Coulter	In-house assay LLQ=35 IU/ml <sup>53</sup>
Zambia	Lusaka	Sinkala & Vinikoor	Referral hospital	2005	283	Yes	WHO AUDIT-C	Multiple platforms	In-house; Cobas Ampliprep/Taqman, Roche & GeneXpert HBV, Cepheid
Senegal	Dakar	Fall	Referral hospital	2005	97	No	WHO AUDIT	Cobas 6000, Roche	Cobas Ampliprep/Taqman v1.0, Roche
Senegal	Thies	Lemoine	Referral hospital	2005	300	No	>20g/day (none reported)	VITROS 350, Ortho	HBV Realtime, m2000sp/rt, Abbott
South Africa	Stellenbosch	Maponga	Referral hospital	1990	85	No	Not reported	Architect, Abbott	HBV Realtime, m2000sp/rt, Abbott
Senegal	Dakar	Seydi & Wandeler	Referral hospital	2005	303	No	Not reported	CYNSTART, Cypress Diagnostics, Belgium	COBAS Ampliprep/TaqMan System, Roche
Burkina Faso	Ouagadougou	Sombie	Referral hospital	2005	35	No	Not reported	Architect ci8000, Abbott	HBV Realtime, m2000sp/rt, Abbott

#### Appendix 4: Description of bivariate random effects model

To calculate sensitivity and specificity, data were pooled using a single-stage individual patient data (IPD) meta-analysis approach. We used a bivariate Bayesian random-effects meta-analysis model for sensitivity and specificity using patient-level covariates with study-level random effects to account for anticipated variability between sites.<sup>21</sup>

Specifically, let  $Y_{i,j}$  be the random variable recording the outcome for participant  $j = 1, \dots, n_i$  in study  $i = 1, \dots, m$  for a specific biomarker  $X$  and a specific threshold  $x_t$  that are currently considered.  $Y_{i,j} = 0$  if  $X_{i,j} < x_t$  and  $Y_{i,j} = 1$  if  $X_{i,j} \geq x_t$ .

Let  $\text{state}_{i,j}$  be the true disease state (according to reference test result, for example cirrhosis present or absent).

The Bayesian bivariate model for sensitivity and specificity is defined by:

$$Y_{i,j} \sim \text{Bernoulli}(p_{i,j})$$

$$\text{logit}(p_{i,j}) = \begin{cases} \beta^{(1)} + \gamma_1^{(1)} \cdot \text{alcohol}_{i,j} + \gamma_2^{(1)} \cdot \text{sex}_{\text{female}_{i,j}} + \gamma_3^{(1)} \cdot \text{BMI}_{\text{underweight}_{i,j}} + \gamma_4^{(1)} \cdot \text{BMI}_{\text{overweight}_{i,j}} + \gamma_5^{(1)} \cdot \text{BMI}_{\text{obese}_{i,j}} + \gamma_6^{(1)} \cdot \text{test reason}_{\text{susp. liver disease}_{i,j}} + u_{1,i} & \text{if } \text{state}_{i,j} = \text{positive} \\ \beta^{(0)} + \gamma_1^{(0)} \cdot \text{alcohol}_{i,j} + \gamma_2^{(0)} \cdot \text{sex}_{\text{female}_{i,j}} + \gamma_3^{(0)} \cdot \text{BMI}_{\text{underweight}_{i,j}} + \gamma_4^{(0)} \cdot \text{BMI}_{\text{overweight}_{i,j}} + \gamma_5^{(0)} \cdot \text{BMI}_{\text{obese}_{i,j}} + \gamma_6^{(0)} \cdot \text{test reason}_{\text{susp. liver disease}_{i,j}} + u_{0,i} & \text{if } \text{state}_{i,j} = \text{negative} \end{cases}$$

where

$$p_{i,j} = \begin{cases} P(Y_{i,j} = 1 | \text{state}_{i,j} = \text{positive}) = \text{sensitivity} & \text{if } \text{state}_{i,j} = \text{positive} \\ 1 - P(Y_{i,j} = 0 | \text{state}_{i,j} = \text{negative}) = 1 - \text{specificity} & \text{if } \text{state}_{i,j} = \text{negative} \end{cases}$$

and  $u_{1,i}, u_{0,i}$  are study-specific random effects

$$(u_{1,i}, u_{0,i})^T \sim N((0,0)^T, \Omega)$$

with  $\Omega$  a 2x2 covariance matrix.

Since we use a Bayesian paradigm to fit the model, we need to specify prior distributions for the model parameters. These are non-informative priors:

$$\beta^{(l)}, \gamma_k^{(l)} \sim N(0, 10^5) \quad l = 0, 1; \quad k = 1, \dots, 6$$

and


$$\Omega^{-1} \sim \text{Wishart}\left(\begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}, 2\right)$$

In the stratified models, the above model is fitted to the data from each stratum based on testing reason (suspected liver disease or other). For those models, the testing reason terms, i.e. the parameters  $\gamma_6^{(l)}$ ,  $l = 0, 1$ , are dropped in the above model specification.

The model further specifies distributions for all variables in the model:  $\text{state}_{i,j}$  (cirrhosis or significant fibrosis present or absent), alcohol,  $\text{sex}_{\text{female}}$  are assumed to follow Bernoulli distributions and body mass index (BMI) a categorical distribution. This specification allows the Bayesian model to handle missing values in the dataset: at each MCMC iteration, for the unobserved data values, the model samples from the specified distributions with the

corresponding distributional parameters learned from the data. As the model is computationally demanding to fit, we used a grid search with 42 (APRI), 41 (GPR), 41 (ALT) and 43 (FIB4) different threshold values evaluated for each biomarker. We aimed for at least 40 different values per biomarker and the slightly different numbers of thresholds per biomarker results from the fact that for some biomarkers several quantiles have the same value.

Appendix 5: Validation of APRI model for cirrhosis using 500 bootstrap samples





## Appendix 6: Ethical approval HEPSANET

### Ethiopia

National Research Ethics Review Committee, Ethiopia (Ref.: 3.10/829/07).

Regional Committee for Medical and Health Research Ethics, Norway (Ref.: 2014/1146).

### Malawi

National Health Sciences Research Committee of Malawi (Ref.: 16/11/1698 and 15/5/1599).

University of Liverpool, UK (Ref.: 1954).

### Zambia

University of Zambia Biomedical Research Ethics Committee (Ref.: 013-09-15).

### South Africa

University of Cape Town Human Research Ethics Committee, South Africa (Ref.: 667/2020).

Stellenbosch University Human Research Ethics Committee, South Africa (Ref.: N17/01/013 and S13/04/072).

University of Oxford Tropical Research Ethics Committee, UK (Ref.: OXTREC 01–18).

### Nigeria

Jos University Research Ethics Committee, Nigeria (Ref.: JUTH/DCS/ADM/127/XIX/5962).

### The Gambia

The Government of The Gambia and Medical Research Council (MRC) Gambia Joint Ethics Committee (Ref.: SCC1266).


### Senegal

Senegalese National Health Research Ethics Committee (Ref.: SEN11/34 and SEN19/11).

### Burkina Faso

Yalgado Ouédraogo University Hospital Center Institutional Review Board, Burkina Faso (Ref.: 0782).

Appendix 7: Flowchart of searches for eligible studies



Abbreviations: AJOL, African Journals Online (<https://www.ajol.info>); AIM, African Index Medicus (<https://www.globalindexmedicus.net/biblioteca/aim/>); TE, transient elastography; HCC, hepatocellular carcinoma; IPD, individual patient data

Appendix 8: Risk of bias assessment using the QUADAS-2 criteria

Country	Ethiopia Addis Ababa	The Gambia Banjul	Senegal 1 Theiès	Senegal 2 Dakar	Senegal 3 Dakar	Senegal 4 Dakar	South Africa Cape Town	South Africa Stellenbosch	Nigera Jos	Malawi Blantyre Hospital/ community	Zambia Lusaka Hospital/ community	Burkina Faso Ouagadougou Hospital
<b>Setting</b>	Hospital	Community	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital
<b>1. PATIENT SELECTION</b>												
Was a consecutive or random sample enrolled	Yes	Yes	Yes	Yes	Yes	Yes	No	No <sup>c</sup>	Yes	Yes	Yes	Yes
Was a case-control design avoided?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Did the study avoid inappropriate exclusions?	Yes	Yes	Yes	Yes		Yes	Yes	Yes	Yes	Yes	Yes	Yes
Could the selection of patients have introduced bias?	No	No	No	Yes <sup>a</sup>	Yes <sup>b</sup>	No	Yes	Yes <sup>c</sup>	Yes <sup>d</sup>	Yes <sup>e</sup>	No	Yes <sup>f</sup>
Is there concern that the included patients do not match the review question?	No	No	No	Yes <sup>a</sup>	Yes <sup>b</sup>	No	No	Yes <sup>c</sup>	No	No	No	No
<b>2. INDEX TESTS</b>												
Were the index tests interpreted without knowledge of the reference standard?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Could the conduct or interpretation of the index test have introduced bias?	No	No	No	No	No	No	No	No	No	No	No	No
Is there concern the the index test , its conduct or interpretation differ from the review question?	No	No	No	No	No	No	No	No	No	No	No	No
<b>3. REFERENCE TESTS</b>												
Is the reference standard likely to correctly classify the target condiciton?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Were the reference standard results interpreted without knowledge of the results of the index test?	Unclear	Unclear	Unclear	Unclear	Unclear	Yes	No	No	Unclear	Yes	Yes	Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias?	No	No	No	No	No	No	No	No	No	No	No	No
<b>4. FLOW AND TIMING</b>												
Was there an appropriate interval between index tests and reference standard?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Did all patients receive a reference standard?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No <sup>c</sup>	Yes	Yes	No	No
Did patients receive the same reference standard?	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No
Were all patients included in the analysis?	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	No	No
Could the patient flow have introduced bias?	No	No	No	No	No	No	Yes	Yes <sup>c</sup>	No	Yes <sup>g</sup>	Yes <sup>g</sup>	No

<sup>a</sup> Inclusion criteria were inactive HBV carriers with HBV DNA <2000 IU/ml, normal ALT, HBeAg negative.

<sup>b</sup> Inclusion criteria were HBsAg positive for 6 months, treatment naïve, symptom free with HBV DNA >3.2 log<sub>10</sub> IU/ml.

<sup>c</sup> Subset of patients underwent TE examination at clinicians' discretion - standardised criteria not provided.

<sup>d</sup> Excluded patients with significant alcohol consumption or body mass index >28 kg/m<sup>2</sup>.


<sup>e</sup> Hospital study recruited patients with suspected cirrhosis based on clinical symptoms or signs suggestive of chronic liver disease.

<sup>f</sup> Only patients undergoing a liver biopsy were included, although this was standard of care at the time for all HBV patients.

<sup>g</sup> Loss to follow up occurred from community diagnosis to treatment eligibility assessment with 94/150 (63%) of HBsAg positive patients being evaluated.

<sup>h</sup> Loss to follow up occurred from referral of patients from the community study to clinical staging at the hospital site with 148/182 (80%) of HBsAg patients having treatment eligibility assessment, of whom 49/148 (33%) had transient elastography.

Appendix 9: Association of cirrhosis prevalence with age, sex, and reason for hepatitis B testing<sup>a</sup>



<sup>a</sup> Graphs show restricted cubic splines with three knots with respect to age. Shaded areas surrounding central estimates represent 95% confidence intervals.

Appendix 10: Associations with cirrhosis (model 1) and significant fibrosis (model 2) among HEPSANET participants: mixed effects logistic regression model<sup>a</sup>

**Model 1: Cirrhosis (>12.2kPa)**

Variable	Univariable association			Multivariable model		
	Odds ratio	(95% CI)	P value	Odds ratio	(95% CI)	P value
Age (per year)	1.03	(1.02 – 1.04)	<0.001	1.03	(1.01 – 1.04)	<0.001
Sex (male vs female)	3.55	(2.52 – 5.00)	<0.001	3.31	(2.19 – 5.00)	<0.001
BMI			<0.001			0.06
Underweight	0.94	(0.62 – 1.43)		0.90	(0.56 – 1.45)	
Normal	Reference			Reference		
Overweight	0.46	(0.30 – 0.69)		0.58	(0.37 – 0.93)	
Obese	0.33	(0.14 – 0.77)		0.45	(0.17 – 1.21)	
Suspected liver disease (reference asymptomatic screening)	45.6	(25.8 – 80.7)	<0.001	55.5	(28.1 -109.5)	<0.001

**Model 2: Significant fibrosis (>7.9kPa)**

Variable	Univariable association			Multivariable model		
	Odds ratio	(95% CI)	P value	Odds ratio	(95% CI)	P value
Age (per year)	1.01	(1.00 – 1.02)	0.022	1.01	(1.00 – 1.02)	0.07
Sex (male vs female)	3.38	(2.70 – 4.23)	<0.001	3.42	(2.63 – 4.45)	<0.001
BMI			<0.001			0.005
Underweight	0.99	(0.73 – 1.35)		0.92	(0.66 – 1.30)	
Normal	Reference			Reference		
Overweight	0.49	(0.37 – 0.65)		0.60	(0.44 – 0.81)	
Obese	0.46	(0.28 – 0.76)		0.65	(0.37 – 1.12)	
Suspected liver disease (reference asymptomatic screening)	8.3	(6.4 – 10.9)	<0.001	9.91	(7.16 – 13.7)	<0.0001

<sup>a</sup>Models include random effects for study site

Appendix 11: Diagnostic performance characteristics at each site, stratified by reason for testing using APRI with rule-out threshold of 0.65 for the diagnosis of cirrhosis

Site	Asymptomatic screening populations					Liver disease populations				
	Pr (%)	PPV (%)	NPV (%)	Sensitivity (%)	Specificity (%)	Pr (%)	PPV (%)	NPV (%)	Sensitivity (%)	Specificity (%)
Ethiopia	0.6	0.0 (0-97.5)	99.4 (98.6-99.8)	0.0 (0 - 60.2)	99.9 (99.2-100)	36.5	61.0 (49.6-71.6)	72.0 (65.8 - 77.6)	42.7 (33.6- 52.2)	84.3 (78.6 - 89.0)
Cape Town	3.7	20.0 (2.6-55.6)	98.0 (92.9-99.8)	50.0 (6.8 - 93.2)	92.4 (85.5-96.7)	8.9	16.7 (0.4 - 64.1)	92.3 (79.1 - 98.4)	25.0 (0.6 - 80.6)	87.8 (73.8 - 95.9)
Senegal 1	0	-	100.0	-	96.2 (89.3-99.2)	0.0	-	100	-	100.0 (39.8 - 100)
Malawi	2.7	25.0 (0.6-80.6)	98.5 (92.0-100)	50.0 (1.3 - 98.7)	95.7 (87.8 - 99.1)	91.7	95.2 (83.3 - 98.8)	50.0 (8.6 -91.4)	95.2 (76.2 - 99.9)	50.0 (1.3 - 98.7)
Nigeria						12.1	48.8 (33.3 - 64.5)	98.6 (95.2 - 99.8)	91.3 (72.0 - 98.9)	86.8 (80.7 - 91.6)
Stellenbosch	11.6	50.0 (11.8-88.2)	96.7 (82.8-99.9)	75.0 (19.4 - 99.4)	90.6 (75.0 - 98.0)					
Zambia	2.1	0.0 (0-14.8)	96.2 (87.0-99.5)	0.0 (0- 84.2)	68.9 (57.1 - 79.2)	54.6	57.1 (18.4 - 90.1)	66.7 (9.4 - 99.2)	80.0 (28.4 - 99.5)	40.0 (5.3 - 85.3)
Gambia	1.3	5.5 (2.2 - 10.9)	99.5 (98.7-99.9)	70.0 (34.8 -93.3)	84.3 (81.6 -86.8)					
Senegal 2	9.5	32.3 (16.7 - 51.4)	96.7 (91.7-99.1)	71.4 (41.9 - 91.6)	84.7 (77.5 - 90.3)					
Burkina Faso										
Senegal 3	6.6	37.5 (18.8 - 59.4)	96.4 (93.3-98.3)	50.0 (26.0 - 74.0)	94.2 (90.6 - 96.7)					
Senegal 4	1.3	20.0 (0.5 - 71.6)	99.1 (96.7-99.9)	33.3 (0.8 - 90.6)	98.2 (95.4- 99.5)	6.9	33.3 (0.8 - 90.6)	93.9 (85.2 - 98.3)	20.0 (0.5 - 71.6)	96.9 (89.2 - 99.6)

**Abbreviations** APRI, aspartate aminotransferase-to-platelet ratio index; Pr, Prevalence of cirrhosis; PPV, positive predictive value; NPV, negative predictive value

Appendix 12: Association between participant characteristics and biomarker sensitivity and specificity for the diagnosis of cirrhosis (>12.2kPa) with APRI and GPR set at rule-in thresholds: Bayesian bivariate random effects model<sup>a</sup>


<b>Biomarker, threshold</b>	<b>Sensitivity</b>	<b>Specificity</b>
<b>Participant characteristics</b>	<b>Odds ratio, posterior mean (95% HDI credible interval)</b>	<b>Odds ratio (posterior mean) 95% HDI credible interval</b>
<b>APRI 0.65</b>		
Hazardous alcohol consumption	1.19 (0.11 – 2.79)	0.53 (0.24, 0.86)
Underweight	1.41 (0.43 – 2.67)	0.92 (0.57 – 1.33)
Overweight	1.27 (0.31 – 2.63)	1.44 (0.43 – 2.67)
Obese	1.00 (0.00 – 3.10)	2.15 (0.85 – 3.92)
Suspected liver disease	4.96 (0.67 – 1.67)	0.13 (0.06 – 0.21)
Female sex	1.66 (0.53 – 3.17)	2.26 (1.63 – 2.96)
Random effects variance (logit)	0.88 (0.09 – 2.19)	1.27 (0.35, 2.64)
Reference sensitivity/specificity <sup>a</sup>	0.50 (0.32 – 0.68)	0.93 (0.91 – 0.95)
<b>GPR 0.47</b>		
Hazardous alcohol consumption	3.00 (0.16 – 8.38)	0.22 (0.07 – 0.41)
Underweight	1.27 (0.24 – 2.66)	1.08 (0.51 – 1.78)
Overweight	1.31 (0.17 – 3.17)	0.57 (0.35 – 0.81)
Obese	0.40 (0.00 – 1.48)	0.72 (0.30 – 1.24)
Suspected liver disease	3.86 (0.39 – 9.85)	0.32 (0.15 – 0.50)
Female sex	0.93 (0.14 – 1.99)	2.64 (1.68 – 3.68)
Random effects variance (logit)	1.27 (0.10 – 3.38)	0.94 (0.20 – 2.10)
Reference sensitivity/specificity <sup>a</sup>	0.60 (0.39 – 0.79)	0.94 (0.91 – 0.96)

Abbreviations: HDI, highest density interval; APRI, Aspartate aminotransferase-to-platelet ratio index; GPR, gamma-glutamyl transferase-to-platelet ratio.

<sup>a</sup> Reference category is a male with normal body mass index (18.5-24.9 kg/m<sup>2</sup>), without hazardous alcohol consumption, with HBsAg testing conducted for asymptomatic screening. We derived odds ratios (for sensitivity and specificity respectively) for the fixed factors included in the bivariate mixed effects logistic regression model. An odds ratio >1 indicates that the corresponding covariate, on average, increases the sensitivity (or specificity), and an odds ratio <1 indicates that the covariate decreases on average the sensitivity (or specificity).




Appendix 13: Sensitivity analyses of rule-in and rule-out thresholds for APRI assessing the effect of exclusion of patients with ascites, use of sex-specific and centre-specific upper limits of normal, and use of an alternative liver stiffness threshold of 9.5 kPa to define cirrhosis




**Appendix 14: Association between liver stiffness measurement and test sensitivity for APRI: Liver stiffness distribution stratified by APRI classification (A & B) and sensitivity of APRI relative to liver stiffness (C & D) among patients with cirrhosis**


A: APRI, rule-in (threshold 0.65)




B: APRI, rule-out (threshold 0.36)



C: APRI, rule-in (threshold 0.65)



D: APRI, rule-out (threshold 0.36)



<sup>a</sup> Kernel density plots (A&B) show distribution of median liver stiffness measurements among patients with cirrhosis, stratified by the result of APRI classification at the rule-in (A) and rule-out (B) thresholds. The association between the sensitivity of APRI at rule-in (C) and rule-out (D) thresholds with liver stiffness measurement is shown using a restricted cubic spline with 5 knots, with shaded areas indicating 95% confidence intervals.